Physician profile
Ryan D Reber
NPI 1134352255
$93,765.32
in general payments reported to CMS, 2019-2025
41 companies · $6,862 in 2025
The $6,862 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $14K · 2021: $8,322 · 2022: $15K · 2023: $12K · 2024: $7,353 · 2025: $6,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $3,973 · Travel and Lodging: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,020.14 |
| Food and Beverage | $3,972.52 |
| Travel and Lodging | $1,001.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $78,503.83 | 2019-2024 | Yupelri, Yupelri |
| Viatris Specialty LLC | $5,006.88 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $2,553.40 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,383.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,255.00 | 2019-2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $898.49 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.35 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Mylan INC. | $662.50 | 2021 | |
| Philips North America LLC | $461.66 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $323.85 | 2019-2024 | Dupixent |
| Genzyme Corporation | $258.95 | 2019-2025 | |
| Genentech USA, INC. | $165.54 | 2019-2025 | Xolair |
| Harmony Biosciences LLC | $119.82 | 2023-2025 | Wakix |
| Amgen INC. | $117.34 | 2022-2025 | Tezspire |
| Electromed, INC. | $109.99 | 2022-2024 | Smartvest |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Reber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.